Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban in Patients With Mitral Stenosis and Atrial Fibrillation
NCT03926156Phase 3Terminated
- Sponsor
- Rajaie Cardiovascular Medical and Research Center
- Start
- May 2019
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rivaroxaban in mitral stenosis (MS) and Atrial fibrillation (AFib) (2 arms), sponsored by Rajaie Cardiovascular Medical and Research Center. Primary endpoints: Number of participants with stroke at 12 months and Number of participants with systemic embolic event at 12 months. Started May 2019; status: terminated.
02
Drugs
rivaroxaban
03
Conditions
mitral stenosis (MS)Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT03926156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03926156.